• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转录因子 HNF-1β 抑制人卵巢透明细胞的细胞死亡并诱导 G2 期阻滞积累:细胞检查点激酶 CHK1 调节化学敏感性。

Inhibition of cell death and induction of G2 arrest accumulation in human ovarian clear cells by HNF-1β transcription factor: chemosensitivity is regulated by checkpoint kinase CHK1.

机构信息

*Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Nara; †Section of Translational Research, Hyogo Cancer Center, Akashi, Hyogo; ‡Department of Pathology, Nara Medical University, Kashihara, Nara; and §Department of Obstetrics and Gynecology, Yao Municipal Hospital, Yao-city, Osaka, Japan.

出版信息

Int J Gynecol Cancer. 2014 Jun;24(5):838-43. doi: 10.1097/IGC.0000000000000136.

DOI:10.1097/IGC.0000000000000136
PMID:24804869
Abstract

OBJECTIVE

Appropriate cell cycle checkpoints are essential for the maintenance of normal cells and chemosensitivity of cancer cells. Clear cell adenocarcinoma (CCA) of the ovary is highly resistant to chemotherapy. Hepatocyte nuclear factor-1β (HNF-1β) is known to be overexpressed in CCA, but its role and clinical significance is unclear. We investigated the role of HNF-1β in regulation of the cell cycle in CCA.

METHODS

To clarify the effects of HNF-1β on cell cycle checkpoints, we compared the cell cycle distribution and the expression of key proteins involved in CCA cells in which HNF-1β had been stably knocked down and in vector-control cell lines after treatment with bleomycin. HNF-1β (+) cells were arrested in G2 phase because of DNA damage.

RESULTS

HNF-1β (-) cells died because of a checkpoint mechanism. G2 arrest of HNF-1β (+) cells resulted from sustained CHK1 activation, a protein that plays a major role in the checkpoint mechanism. HNF-1β (+) cells were treated with a CHK1 inhibitor after bleomycin treatment. Flow cytometric analysis of the cell cycle demonstrated that DNA damage-induced G2-arrested cells were released from the checkpoint and killed by a CHK1 inhibitor.

CONCLUSIONS

The chemoresistance of CCA may be due to aberrant retention of the G2 checkpoint through overexpression of HNF-1β. This is the first study demonstrating cell cycle regulation and chemosensitization by a CHK1 inhibitor in CCA.

摘要

目的

适当的细胞周期检查点对于维持正常细胞和癌细胞的化疗敏感性至关重要。卵巢透明细胞腺癌(CCA)对化疗具有高度耐药性。已知肝细胞核因子-1β(HNF-1β)在 CCA 中过度表达,但它的作用和临床意义尚不清楚。我们研究了 HNF-1β在调节 CCA 细胞周期中的作用。

方法

为了阐明 HNF-1β对细胞周期检查点的影响,我们比较了 HNF-1β稳定敲低的 CCA 细胞和载体对照细胞系在博来霉素处理后细胞周期分布和关键蛋白表达的变化。由于 DNA 损伤,HNF-1β(+)细胞被阻滞在 G2 期。

结果

HNF-1β(-)细胞由于检查点机制而死亡。HNF-1β(+)细胞的 G2 期阻滞是由于持续的 CHK1 激活所致,CHK1 是检查点机制中的主要蛋白。用 CHK1 抑制剂处理 HNF-1β(+)细胞后,对细胞周期进行流式细胞术分析表明,DNA 损伤诱导的 G2 期阻滞细胞通过 CHK1 抑制剂从检查点释放并被杀死。

结论

CCA 的化疗耐药性可能是由于 HNF-1β的过度表达导致 G2 检查点异常保留。这是第一项研究表明 CHK1 抑制剂在 CCA 中调节细胞周期和增敏作用。

相似文献

1
Inhibition of cell death and induction of G2 arrest accumulation in human ovarian clear cells by HNF-1β transcription factor: chemosensitivity is regulated by checkpoint kinase CHK1.转录因子 HNF-1β 抑制人卵巢透明细胞的细胞死亡并诱导 G2 期阻滞积累:细胞检查点激酶 CHK1 调节化学敏感性。
Int J Gynecol Cancer. 2014 Jun;24(5):838-43. doi: 10.1097/IGC.0000000000000136.
2
The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary.肝细胞核因子-1β在卵巢透明细胞癌发病机制中的作用
Int J Gynecol Cancer. 2009 Apr;19(3):471-9. doi: 10.1111/IGC.0b013e3181a19eca.
3
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
4
Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.哺乳动物雷帕霉素靶蛋白(mTOR)抑制导致卵巢透明细胞腺癌缺氧诱导因子信号通路改变:临床试验的体内外探索。
Int J Gynecol Cancer. 2013 Sep;23(7):1210-8. doi: 10.1097/IGC.0b013e31829d2d51.
5
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
6
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
7
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
8
Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy.抑制极光激酶A协同增强顺铂诱导的卵巢透明细胞癌细胞系的细胞毒性:一种潜在的治疗策略。
Int J Gynecol Cancer. 2017 Oct;27(8):1666-1674. doi: 10.1097/IGC.0000000000001081.
9
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.

引用本文的文献

1
Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma.靶向卵巢透明细胞癌中的DNA损伤反应通路
Front Oncol. 2021 Oct 19;11:666815. doi: 10.3389/fonc.2021.666815. eCollection 2021.
2
Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma.由HNF1B调控的卵巢透明细胞癌中线粒体代谢的获得性进化
Cancers (Basel). 2021 May 17;13(10):2413. doi: 10.3390/cancers13102413.
3
GSK-3β mediates the effects of HNF-1β overexpression in ovarian clear cell carcinoma.糖原合成酶激酶-3β介导肝细胞核因子-1β过表达在卵巢透明细胞癌中的作用。
Exp Ther Med. 2020 Nov;20(5):122. doi: 10.3892/etm.2020.9250. Epub 2020 Sep 21.
4
Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer.奥拉帕利联合西妥昔单抗和放疗治疗重度吸烟局部晚期头颈部鳞癌患者的 I 期临床试验的最终报告。
Clin Cancer Res. 2018 Oct 15;24(20):4949-4959. doi: 10.1158/1078-0432.CCR-18-0467. Epub 2018 Jul 3.
5
Conceptual frameworks of synthetic lethality in clear cell carcinoma of the ovary.卵巢透明细胞癌中合成致死的概念框架。
Biomed Rep. 2018 Aug;9(2):112-118. doi: 10.3892/br.2018.1114. Epub 2018 Jun 20.
6
The HNF-1β-USP28-Claspin pathway upregulates DNA damage-induced Chk1 activation in ovarian clear cell carcinoma.HNF-1β-USP28-Claspin通路上调卵巢透明细胞癌中DNA损伤诱导的Chk1激活。
Oncotarget. 2018 Apr 3;9(25):17512-17522. doi: 10.18632/oncotarget.24776.
7
Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.在卵巢透明细胞癌治疗中作为聚(ADP-核糖)聚合酶(PARP)抑制剂潜在合成致死伙伴的物质。
Biomed Rep. 2017 Nov;7(5):391-399. doi: 10.3892/br.2017.990. Epub 2017 Sep 27.
8
Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma.用于诊断卵巢透明细胞癌的新型生物标志物候选物。
Oncol Lett. 2015 Aug;10(2):612-618. doi: 10.3892/ol.2015.3367. Epub 2015 Jun 11.
9
Checkpoint kinase 1 inhibitors as targeted molecular agents for clear cell carcinoma of the ovary.作为卵巢透明细胞癌靶向分子药物的检查点激酶1抑制剂
Oncol Lett. 2015 Aug;10(2):571-576. doi: 10.3892/ol.2015.3268. Epub 2015 May 26.
10
Oxidative Stress and Antioxidant Defense in Endometriosis and Its Malignant Transformation.子宫内膜异位症及其恶性转化中的氧化应激与抗氧化防御
Oxid Med Cell Longev. 2015;2015:848595. doi: 10.1155/2015/848595. Epub 2015 Jun 21.